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Abstract 
Females tend to be underrepresented in clinical trials because of risk to fetus and child-bearing potential. Those that 
do participate tend to be Caucasian and beyond child-bearing age. Several studies including The Multi-Center 
Diversity Study have begun to address this issue and delve into other barriers that inhibit participation such as 
demographics, race, religion and socioeconomic status. Several questions of the survey pertain to the patients race, 
prior participation in clinical trials, and if they are currently pregnant or have children. The data from the surveys 
shows that Hispanics and Asians are less likely to participate in clinical trials than Caucasians. It also shows that 
there is no statistically significant difference in participation in clinical trials between Caucasians who are currently 
pregnant or have children and minorities that meet the same criteria.  
Introduction 
Clinical trials are the gateway to finding more effective 
treatment and medication for all members of society 
regardless of race, ethnicity, religion, gender and 
socioeconomic status. In order to be all inclusive, a 
clinical trial must show a true sampling of the 
population showing diversity in the aforementioned 
areas. In prior studies, females and minorities tend to be 
underrepresented or excluded from clinical trials. It is 
important to include these groups because not all 
medication is effective or has the same side-effects that 
are presented in Caucasian males. One example that 
shows the variability is that after twenty years on the 
market the Food and Drug Administration (FDA) “cut 
the recommended dosage of Ambien for women in 
half” because women “process the drug more slowly 
than men” in turn causing them to have prolonged 
drowsiness” (Jacoby). 
Women and minorities stray away from clinical trials 
because of their beliefs, attitude and knowledge of prior 
studies. For example, in the Tuskegee syphilis study 
“400 illiterate, black, syphilitic male subjects had been 
denied treatment for syphilis for more than 30 years” 
(McCarthy). Studies such as the Tuskegee syphilis 
study influence the attitudes and distrust of African 
Americans in today’s society; therefore, knowledge of 
research that has been performed in the past tends to 
result in future generations declining to participate in 
clinical trials.   
The underrepresentation of females and minorities 
stems not only from the individual’s attitude and 
knowledge, but also the unwillingness of researchers to 
enroll these individuals because of increased variability 
and vulnerability. Many women are excluded from 
clinical trials because of fear that it will affect future 
child-bearing. Pregnant women are also less likely to 
participate in clinical trials because of increase risk to 
the fetus as well as the mother. The fear of causing 
harm to the fetus can be attributed to past studies such 
as the Thalidomide tragedy which caused severe birth 
defects and lead to the FDA “prohibiting 
pharmaceutical companies and others engaged in 
testing of drugs from including pregnant women and 
women of childbearing potential in Phase I drug trials" 
(McCarthy). Besides Thalidomide, Accutane, a drug 
used to treat acne, was found to cause birth defects even 
if it was taken “briefly during the first trimester, a time 
when many women do not yet know they are pregnant” 
(Krause). The vulnerability of the fetus makes pregnant 
women less likely to partake in research. Besides for 
risk to future pregnancy and current pregnancy, many 
women decide not to participate in research because 
they already have children at home that need their 
support and time.  
Various factors influence whether or not an individual 
will be willing to participate in a clinical trial. In order 
to bridge the gap and increase participation of women 
and minorities in clinical trials, we must analyze what 
factors motivate them intrinsically and extrinsically, in 
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turn shedding light on what needs to be provided to 
these individuals in order for them to participate. The 
Multi-Center Diversity Study aims to delve into factors 
that motivate individuals to participate in clinical trials 
while taking into account demographics and race.  
Methods 
An IRB approved survey was used to assess various 
factors that influence female participation in research. 
The survey was offered in English, Spanish, Traditional 
Chinese and Simplified Chinese. Qualified individuals 
were trained to administer the survey at Lehigh Valley 
Health Network, Drexel University, Christiana Care, 
Saint Peter’s University Hospital, Columbia University, 
and Virtua. The surveys were administered in the 
waiting room to female patients who were at least 
eighteen years of age and were both mentally and 
physically able to complete the survey independently. 
Data collected from the surveys was entered in a 
database and analyzed. 
Results 
The data that was used for analysis was preliminary. 
See data tables located in the appendix. 
 
Conclusion/Discussion 
Out of the 400 patients that were surveyed 75% were 
minorities, 25% were Caucasian and 4% non-
categorizable (Figure 1). The data shows that the 
majority of patients who were surveyed were 
minorities; however, only 21/300 (7.0%) of the 
minorities that were surveyed were pregnant or had 
children and had participated in a clinical trial before 
compared to 8/84 (9.25%) of Caucasians that meet the 
same criteria (Figure 2). Based on this data it is clear 
that Caucasians that are pregnant or have children are 
more likely to participate in research than minorities 
that meet the same criteria. 
For further analysis, minorities were categorized as 
follows: Black or African American, Asian, Native 
Hawaiian or Pacific Islander, American Indian or 
Alaska Native, Hispanic/Latina/Mexican/Puerto 
Rican/Dominicana/ Columbian/Spanish and Other. A 
multiple regression analysis was then performed to 
determine if race was a significant barrier to 
participation in clinical trials. The p-values that were 
found to be significant were the following: Hispanic 
p=.06 and Asian p=.004. All other p-values were found 
to be insignificant (Figure 5). Based on the p-values 
obtained from Asians and Hispanics these patients are 
less likely to participate in clinical trials then 
Caucasians.  
Another multiple regression analysis was performed to 
determine if minorities who were pregnant or have 
children are less likely to participate in research than 
Caucasians that meet the same criteria. Both were 
found to be insignificant with the following p-values: 
pregnant p=.72 and has children p=.16 (Figure 6). 
Based on this data it is clear that there is no statistical 
difference between participation in clinical trials in 
Caucasians who are pregnant or have children and 
minorities that meet the same criteria.  
The data shows that Hispanics and Asians are less 
likely to participate in clinical trials than Caucasians. It 
also shows that there is no statistically significant 
difference in participation in clinical trials between 
Caucasians who are currently pregnant or have children 
and minorities that meet the same criteria. However, 
since preliminary data was used in the analysis, no final 
conclusions can be drawn at this point because the final 
analysis might reveal a different outcome.  
Even though 400 patients were surveyed, some 
limitations existed. One limitation is that the majority 
of the patients who were surveyed were Hispanic. 
Many other minorities such as Native Hawaiian and 
American Indian were not represented in the data set. A 
larger more diverse study would be needed to obtain 
more conclusive data. Another limitation is that many 
patients declined to fill out the survey.  
For further investigation one can look to see if there is a 
correlation between minorities and how often they 
decide to seek care and which family member has the 
biggest impact in determining if they should participate 
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Preliminary data was used to complete the following analysis.  
 
 
Figure 1 shows that out of 400 patients surveyed 75% were minorities, 25% were Caucasian and 4% were non-
categorizable. 
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Figure 2 shows how many female minorities and Caucasian females have participated in clinical trials in the past 











































Minorities Who Participated in Clinical 
Trials Previously & Are Pregnant/Have 
Children vs. Caucasians Who Participated 
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Figure 4 represents the specific races of the minorities that participated in clinical trials before, were currently  






Race of Minorites that Participated in 










Black/African American  0.65 
Asian  0.004 
Native Hawaiian/Pacific Islander  0.67 
Hispanic  0.06 
Other  0.40 
Multiracial  0.11 
 
Figure 5 represents whether or not there is a significant difference between Caucasians who participated in clinical 




Black/African American  0.62 
Asian 0.01 
Native Hawaiian/Pacific Islander 0.79 
Hispanic  0.05 
Other 0.46 
Multiracial 0.13 
Pregnant  0.72 
Has Children 0.16 
 
Figure 6 represents whether or not there is a significant difference between Caucasians who participated in clinical 
trials and are pregnant/have kids and minorities who meet the same criteria.  
 
 
